6 completed, 4 unknown, 1 withdrawn. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Completed 6, Unknown 4, Withdrawn 1 |
Follow moxonidine: new trials by email Literature Review of moxonidine trials Research Report on moxonidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome perindopril + moxonidine - Arterial Hypertension, Metabolic Syndrome | Phase 4 | Unknown | Sergey V. Nedogoda | 120 | 2019-03-11 | 2019-07-23 |
| Role of Sympathetic Activation in Ischemia Reperfusion Injury Moxonidine 0.2 MG, placebo - Central Sympathetic Nervous System Diseases | Phase 4 | Completed | Royal Perth Hospital | 46 | 2015-07-08 | 2022-09-29 |
| Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension Moxonidine 0.4 MG, Amlodipine 5mg - Obesity, Hypertension | Phase 4 | Unknown | Royal Perth Hospital | 120 | 2015-06-24 | 2022-09-29 |
| Moxonidine for Prevention of Post-ablation AFib Recurrences Moxonidine, Placebo - Atrial Fibrillation | Phase 4 | Completed | Spyridon Deftereos | 150 | 2012-08-01 | 2014-05-06 |
| Alleviating the Metabolic Side Effects of Antipsychotic Medications Moxonidine, Placebo - Schizophrenia | Phase 4 | Withdrawn | Baker Heart and Diabetes Institute | 2012-05-01 | 2019-04-24 | |
| Polycystic Ovary Syndrome - Improving Outcomes Moxonidine, Placebo - Polycystic Ovary Syndrome | Phase 4 | Completed | Baker Heart and Diabetes Institute | 42 | 2012-05-01 | 2018-11-02 |
| The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension Moxonidine, Irbesartan - Abdominal Obesity, Hypertension | Phase 4 | Unknown | Baker Heart and Diabetes Institute | 100 | 2012-01-01 | 2012-02-03 |
| Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Moxonidine, Placebo - Diabetic Nephropathies | Phase 4 | Completed | Baker Heart and Diabetes Institute | 48 | 2011-04-01 | 2023-09-14 |
| Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Moxonidine (Physiotens), Dietary intervention - Obesity, Overweight | Phase 4 | Unknown | Baker Heart and Diabetes Institute | 77 | 2010-09-01 | 2013-11-05 |
| Treatment of Adiposity Related hypErTension (TARGET) Aliskiren, Moxonidine, Hydrochlorothiazide - Hypertension, Abdominal Obesity | Phase 4 | Completed | UMC Utrecht | 32 | 2010-08-01 | 2012-02-24 |
| Moxonidine Effects on Neuropeptide Y Moxonidine - Obesity, Hypertension | Phase 4 | Completed | Aristotle University Of Thessaloniki | 90 | 2010-01-11 | 2021-12-07 |
Hypertension (5) · Obesity (4) · Metabolic Syndrome (2) · Obesity, Abdominal (2) · Atrial Fibrillation (1) · Depression (1) · Diabetic Nephropathies (1) · Ischemia (1) · Mental Disorders (1) · Overweight (1) · Polycystic Ovary Syndrome (1) · Recurrence (1) · Schizophrenia (1)
Baker Heart and Diabetes Institute (5) · Royal Perth Hospital (2) · Aristotle University Of Thessaloniki (1) · Sergey V. Nedogoda (1) · Spyridon Deftereos (1) · UMC Utrecht (1)
Australia (7) · Greece (1) · Netherlands (1) · Russia (1)
Abdul Khalid (1) · David Barton (1) · Eleni Karlafti, MD, PhD (1) · Gavin Lambert (1) · Gavin Lambert, Dr (1) · Gavin W Lambert, BSc PhD (1) · Markus P Schlaich, MD (1) · Markus Schlaich, MD (1) · Markus Schlaich, MD,FAHA,FESC (1) · Sergey V. Nedogoda, Professor (1) · W. Spiering, MD PhD (1)
PMID 25147079, PMID 25847478, PMID 28865109, PMID 29085669, PMID 30410448, PMID 30520854, PMID 30548504, PMID 32847570